Contact

T: +49 (0) 6172 608-4030
leif.heussen@fresenius.com

Documents

Text as PDF document (PDF, 105 KB)

Fresenius Medical Care, the world’s leading provider of dialysis products and services, is joining through its Schweinfurt facility a Bavarian government initiative that aims to show how a strong economy is fully compatible with a healthy environment. The “Umweltpakt Bayern” (Bavaria environmental pact) includes a range of discussion and working groups where companies and public authorities in the German federal state can exchange views and expertise on topics such as climate, energy consumption and the sustainable use of resources.

In these forums, Fresenius Medical Care will be contributing know-how and experience in environmental management gained at its plant and development facility in Schweinfurt, a city in northern Bavaria about 120 kilometers (75 miles) east of Frankfurt.

Through efficient environmental and energy management based on the ISO standards 14001 and 50001, the Schweinfurt facility has steadily reduced its environmental impact while continuing to offer a safe, healthy workplace for all employees. By converting from oil to district heating, total CO2 emissions were cut by more than 30 percent. Measures including the systematic conversion to LED lighting and the use of energy-efficient injection molding machines reduced energy consumption, while waste material from the injection molding process is now recycled.

“Here in Schweinfurt we’re proud of our contribution to greater environmental protection,” said Andreas Völker, Plant Manager for Fresenius Medical Care in Schweinfurt. “As part of the Bavaria environmental pact, we are committing to the sustainable production of our life-sustaining medical devices. And the pact offers a valuable platform for exchanging information on technical issues related to environmental protection by companies.”

Opened in 1979, the Schweinfurt facility is Fresenius Medical Care’s most important research and production facility for dialysis machines and other medical devices. The company currently has more than 1,300 employees at the site, about a third of them in research and development.

Helios Germany has published its first sustainability report. Oriented to the internationally established standards of the Global Reporting Initiative, this 60-page document outlines the four main target groups and areas that Germany’s largest private hospital operator has defined for its sustainability strategy: Patients, employees, the environment and compliance. Along with numerous statistics and examples from Helios Germany hospitals,  the report sets out the company’s goals for its future development. Titled ”Für eine gesunde Zukunft” (toward a healthy future), the report is now available in German on www.helios-gesundheit.de. An English version will be published soon.

Helios Germany has published its first sustainability report. Oriented to the internationally established standards of the Global Reporting Initiative, this 60-page document outlines the four main target groups and areas that Germany’s largest private hospital operator has defined for its sustainability strategy: Patients, employees, the environment and compliance. Along with numerous statistics and examples from Helios Germany hospitals,  the report sets out the company’s goals for its future development. Titled ”Für eine gesunde Zukunft” (toward a healthy future), the report is now available in German on www.helios-gesundheit.de. An English version will be published soon.

Fresenius will hold its Annual General Meeting (AGM) on August 28, 2020 as a virtual event. Originally, the AGM was scheduled for May 20, 2020. It had to be postponed due to the coronavirus pandemic. As it is currently impossible to predict for how long the restrictions for large public events will be in effect, Fresenius will use the option provided by the German legislator to hold a virtual event to safeguard the health of shareholders, employees and service providers.

The proposed dividend by the General Partner and the Supervisory Board remains unchanged at €0.84 per share entitled to a dividend.

Shareholders will be provided the possibility to follow the entire AGM on the internet. Fresenius will include further details in the AGM invitation that is to be published in the Federal Gazette (Bundesanzeiger) and on the corporate website in July.

Fresenius will hold its Annual General Meeting (AGM) on August 28, 2020 as a virtual event. Originally, the AGM was scheduled for May 20, 2020. It had to be postponed due to the coronavirus pandemic. As it is currently impossible to predict for how long the restrictions for large public events will be in effect, Fresenius will use the option provided by the German legislator to hold a virtual event to safeguard the health of shareholders, employees and service providers.

The proposed dividend by the General Partner and the Supervisory Board remains unchanged at €0.84 per share entitled to a dividend.

Shareholders will be provided the possibility to follow the entire AGM on the internet. Fresenius will include further details in the AGM invitation that is to be published in the Federal Gazette (Bundesanzeiger) and on the corporate website in July.

Fresenius Medical Care, the world’s leading provider of dialysis products and services, will hold its Annual General Meeting (AGM) on August 27, 2020 as a virtual event. Originally, the AGM was scheduled for May 19, 2020. It had to be postponed due to the coronavirus pandemic. As it is currently impossible to predict for how long the restrictions for large public events will be in effect, Fresenius Medical Care will use the option provided by the German legislator to hold a virtual event to safeguard the health of shareholders, employees and service providers.

The proposed dividend by the General Partner and the Supervisory Board remains unchanged at €1.20 per share entitled to dividend.

Shareholders will be provided the possibility to follow the entire AGM on the internet. Fresenius Medical Care will include further details in the AGM invitation that is to be published in the Federal Gazette (Bundesanzeiger) and on the corporate website in July.

Morphine Sulfate Injection is now available in the United States in the company’s Simplist™ ready-to-administer prefilled syringes in MicroVault packaging. MicroVault packaging is designed to support the secure dispensing of controlled substances, for example via transparent hard plastic packaging allowing bar code scanning and visual inspection as well as a tamper evident seal.

Dr. Sebastian Biedenkopf, currently General Counsel of Robert Bosch GmbH, will join the Management Board of Fresenius as Chief Legal and Compliance Officer, and Labor Relations Director, no later than January 1, 2021. He will succeed Dr. Jürgen Götz, who is leaving the company at his own request at the end of June.

Dr. Biedenkopf, 56, has headed the international legal department of the Bosch Group since September 2013. From 2008 until 2012 he held various positions at Conergy AG in Hamburg, lastly as Chief Financial Officer and interim Chief Executive Officer. He holds a doctorate in law and previously served as General Counsel and Chief Compliance Officer at Maxingvest AG (formerly Tchibo Holding AG) in Hamburg, and in various positions at the Bertelsmann Group.

The Chairman of the Supervisory Board of Fresenius, Dr. Gerd Krick, said: “In Dr. Sebastian Biedenkopf we have won a highly experienced, versatile legal expert with profound knowledge in various areas. With his very strongly developed business skills and international outlook, he will make an outstanding fit for Fresenius, and perfectly complement our proven management team. Great thanks go to Dr. Jürgen Götz for the trustful collaboration over many years and his tireless work. Drawing on deep legal expertise, he made important contributions to our successful growth. I respect his wish to pursue other challenges outside of our company after more than 15 years with Fresenius, and in the name of the Supervisory Board I wish him all the best.”

Stephan Sturm, CEO of Fresenius, said: “Dr. Sebastian Biedenkopf has, in various capacities, helped shape strategies, and will bring many new ideas and perspectives to Fresenius. I am very pleased that I will be working with him, and I am convinced that with his know-how in the Legal and Human Resources areas, as well as company management, he will make an ideal addition to our Management Board. In his new role he will be able to build on what his successor accomplished over the years: I want to thank Jürgen Götz for the always trustful and very collegial collaboration. On behalf of the Management Board and all the employees, I wish him all the best.”

Dr. Sebastian Biedenkopf said: “During the discussions in recent weeks, I have gotten to know Fresenius as a superbly positioned company with an impressive culture. I am very much looking forward to putting my experience and knowledge to work here, and having this opportunity to contribute to the continued successful development of Fresenius.”